Table of contents
Nguyen Injury Lawyer is actively investigating potential lawsuits on behalf of individuals who have experienced NAION (non-arteritic anterior ischemic optic neuropathy), gastroparesis, or other severe gastrointestinal conditions, such as bowel obstruction or cyclic vomiting syndrome, after using Ozempic.
Ozempic, a well-known brand name for semaglutide, is a prescription medication initially approved for managing type 2 diabetes. It has also gained popularity as a weight management aid. However, recent scientific studies suggest that Ozempic, particularly when taken in higher doses, may lead to gastroparesis.
Historically, the Ozempic warning label did not adequately inform patients and healthcare providers about the potential risks of these adverse effects. If you have suffered injuries after taking Ozempic, you may be entitled to financial compensation through a product liability lawsuit.
Lawsuits concerning Ozempic, Rybelsus, Wegovy, Trulicity, and Mounjaro have been consolidated into a multidistrict litigation (MDL) class action. While NAION lawsuits are becoming more prevalent, these vision-loss cases are being handled separately from the MDL, as detailed in the updates below. This page will provide up-to-date information and news regarding the Ozempic litigation, along with insights into the potential settlement values of these cases.
If you believe you have a viable Ozempic lawsuit, contact Nguyen Injury Lawyer today at (713) 747-7777 or through our online contact form at https://www.nguyeninjurylawyer.com/contact for a free consultation.
Ozempic Lawsuit Updates
Nguyen Injury Lawyer is dedicated to providing the latest news and updates on the Ozempic litigation. Please check back regularly, as our attorneys update this page frequently with new developments.
February 16, 2025 – Status Conference Highlights
During the status conference held on February 10, 2026, the Court and legal counsel addressed various administrative and case management issues relevant to the MDL.
The parties presented a comprehensive docket update, including the current number of cases in the MDL, the number of newly filed short-form complaints, and the status of Plaintiff Fact Sheet submissions and compliance. Discussions centered on overall inventory growth, any deficiencies in PFS production, and whether additional case management steps were necessary to maintain discovery progress.
The Court also received updates on related state court litigation in Delaware, Indiana, and New Jersey. Counsel provided an overview of the procedural status of these cases, upcoming trial settings or dispositive motions, and coordination efforts between the MDL and parallel state proceedings.
Management of “mixed-injury” cases, specifically the Brown, Lee, Marsh, Morris, and Ralph matters, was also addressed. These cases involve overlapping or multiple injury theories, raising questions about case administration and discovery sequencing. The judge outlined how these cases would proceed within the MDL framework. Finally, the court considered the pending motion in Daigle seeking to convert a dismissal, with counsel presenting their respective positions on whether the prior dismissal should be modified and its potential impact on the case.
January 17, 2026 – 2026 Litigation Predictions
Nguyen Injury Lawyer anticipates that NAION cases will have significant value. Gastroparesis cases involving long-term, permanent injuries are also expected to be valuable. However, gastroparesis cases where the victim experienced minimal or short-term effects may not be as valuable.
January 6, 2026 – MDL Case Count Reaches 3,097
As of January 2026, the GLP-1 weight loss drug MDL encompasses 3,063 pending cases, with a total of 3,097 cases filed.
December 9, 2025 – Update on MDL Growth
Given the widespread use of Ozempic and other GLP-1-based weight-loss drugs, the related class action MDL continues to expand. In November alone, 27 new cases were added, bringing the total number of filings to 2,947. This upward trend reflects the increasing number of patients alleging undisclosed or insufficiently warned-about side effects.
September 30, 2025 – MDL Case Count Update
The Ozempic / GLP-1 MDL now includes 2,914 pending cases, an increase of 800 new cases since August 1, averaging approximately 200 new cases added each month.
September 30, 2025 – New Lawsuit Filed
In a recent lawsuit, a woman from Cabazon, California, alleges severe and potentially permanent gastrointestinal injuries resulting from Wegovy use.
The plaintiff, who began taking Wegovy in May 2023, claims to have developed ileus, a blockage in the small intestine, followed by a diagnosis of gastroparesis. She asserts that these injuries caused significant pain, vomiting, and required medical intervention, ultimately leading her to discontinue the drug.
The complaint accuses the defendants of failing to adequately warn consumers and physicians about the risk of serious gastrointestinal side effects, including conditions requiring emergency care or hospitalization. The plaintiff further contends that Novo Nordisk aggressively marketed Wegovy as a “miracle” weight-loss drug while downplaying its risks and misleading consumers about its long-term efficacy and safety.
September 21, 2025 – Focus Shifts to NAION
Plaintiffs have faced challenges in proving that gastroparesis was directly caused or worsened by Ozempic, rather than being a pre-existing complication of underlying diabetes.
Consequently, the litigation focus has shifted to vision loss and non-arteritic anterior ischemic optic neuropathy (NAION).
These NAION cases present a more direct and compelling narrative. In August 2024, the European Medicines Agency mandated updated warning labels for Ozempic and related drugs to include vision loss and NAION risk, which plaintiffs’ lawyers can use as regulatory validation. NAION also offers the advantage of being sudden and severe, often resulting in permanent partial or total vision loss in one eye. This clarifies damages and simplifies arguments for causation, particularly in cases without pre-existing diabetes-related eye disease. NAION provides a clearer narrative for juries, and Nguyen Injury Lawyer is now prioritizing these cases.
September 17, 2025 – Short Form Complaint
Attorneys involved in the Ozempic MDL have jointly proposed a Case Management Order adopting a Master Complaint and Short Form Complaint system. This approach streamlines litigation and generally benefits plaintiffs. The short form allows new and existing claimants to file more easily, without needing to repeat every factual allegation.
While Ozempic attorneys will need to refile existing cases using the new format, this is a minor inconvenience. Defendants will have 60 days to respond to the Master Complaint, and motions to dismiss will be tightly managed. Overall, this is a beneficial move that improves case organization.
September 11, 2025 – Lilly Seeks NAION MDL
Eli Lilly has filed a motion to centralize all federal lawsuits alleging vision loss from GLP-1 receptor agonist drugs, specifically claims involving non-arteritic anterior ischemic optic neuropathy (NAION).
The motion requests either the creation of a new MDL, designated “GLP-1 RAs Products Liability Litigation (No. II),” or the consolidation of these NAION cases into the existing MDL No. 3094, which currently handles gastrointestinal injury claims involving the same class of drugs. These include Lilly’s Mounjaro and Trulicity, as well as Novo Nordisk’s Ozempic and Wegovy.
Lilly has specifically requested that the cases be assigned to Judge Karen Marston in the Eastern District of Pennsylvania, who already presides over MDL 3094, citing her familiarity with the relevant science, regulatory history, and case management structure. The company argues that she is the most logical and efficient choice to oversee the expanding litigation.
Lilly’s proactive pursuit of centralization suggests a clear strategy: they prefer Judge Marston to handle these claims.
The motion emphasizes “combination cases” that allege both GI and NAION injuries, arguing that coordinated pretrial proceedings are necessary. However, Lilly’s primary motivation appears to be their belief that Judge Marston is favorable to the defendants in this litigation.
Regardless of whether a new MDL is created, the NAION docket in New Jersey, which handles cases from plaintiffs nationwide, will continue to grow.
September 6, 2025 – Types of Ozempic Claims Being Accepted
Based on Judge Marston’s new order, Nguyen Injury Lawyer is now accepting two types of claims:
- Vision injuries (NAION)
- Gastroparesis confirmed by a gastric emptying study (scintigraphy, breath test, or WMC)
September 5, 2025 – GLP-1 Drug Ingredients
The FDA recently announced a “green list” of foreign manufacturers authorized to supply raw materials for compounded versions of GLP-1 drugs, such as Wegovy and Mounjaro.
This move aims to limit the use of unsafe or counterfeit active pharmaceutical ingredients by compounders while still allowing some compounding under strict quality standards. Although over three dozen overseas suppliers were listed, their names were redacted, and imports from non-listed companies may be detained.
Both Lilly and Novo Nordisk stocks declined following the announcement.
September 1, 2025: FDA Approves Wegovy for Fatty Liver Disease
The FDA has approved Wegovy (semaglutide) for treating metabolic dysfunction-associated steatohepatitis (MASH), a serious form of fatty liver disease in adults with moderate to advanced fibrosis. This is the first GLP-1 drug approved for MASH.
While Wegovy may offer benefits for patients with fatty liver disease, similar to its use for obesity, these benefits must be weighed against the drug’s risks. Informed decision-making is only possible when doctors are fully aware of all relevant safety information.
August 15, 2025: Significant New Ruling
U.S. District Judge Karen Spencer Marston has issued two major rulings that will impact the future of the GLP-1 receptor agonist MDL, which includes over 2,000 cases against Novo Nordisk and Eli Lilly.
In her recent order, the court resolved a cluster of Daubert motions, ruling that plaintiffs’ gastroparesis claims must be supported by objective medical testing. Specifically, Judge Marston stated that “any Plaintiff claiming to suffer (or have suffered) from gastroparesis, must show that their diagnosis is based on a properly performed gastric emptying study.” While this standard may narrow the pool of viable claims, it also clarifies the evidentiary requirements and forces defendants to confront plaintiffs who have diagnostic proof.
This ruling confirms that the litigation will continue. The companies attempted to dismiss twelve of the seventeen counts in the master complaint, arguing that statements about their drugs being “safe and effective” were non-actionable puffery and that design defect theories were federally preempted.
Court Ruling on Initial Ozempic Lawsuits
Judge Marston partially concurred, dismissing claims of design flaws and striking down broad allegations of deceptive omissions in general marketing. However, she rejected the argument that the representations were mere puffery. The plaintiffs successfully identified specific claims regarding safety and efficacy, many promoted by paid scientists and celebrities, that went far beyond general statements. These claims, she determined, “are sufficient to survive dismissal at this early stage of the litigation.” Critically, the court ruled that the omissions from the drugs’ labels, including the absence of warnings about gastroparesis, were pled with sufficient detail to proceed.
For those affected, the rulings have both positive and negative aspects. On one hand, claims of stomach paralysis now require connection to a gastric emptying study or a similar test, potentially excluding individuals whose doctors relied solely on clinical observations. This could unfairly exclude some individuals from the litigation. On the other hand, the core argument remains valid: that Novo and Lilly aggressively promoted GLP-1 drugs for weight loss while concealing known risks, resulting in billions of dollars in profits. Claims related to warranty and labeling are still viable, and the court chose not to dismiss state law negligence and warranty claims at this point. Ultimately, victims who can provide objective evidence of their injuries still have a clear path to trial, and Novo and Lilly will face discovery regarding allegations that they knowingly minimized life-altering side effects in order to dominate the market.
August 14, 2025 – New Jersey NAION Class Action Gaining Momentum
Novo Nordisk may soon be involved in a coordinated mass tort action in New Jersey state court concerning allegations that its popular weight loss medications, Ozempic and Wegovy, caused permanent vision loss.
Over 30 plaintiffs have requested multicounty litigation status, nine more than reported on June 17. The plaintiffs claim that the drugs caused them to develop non-arteritic anterior ischemic optic neuropathy (NAION), a severe and irreversible condition. The proposed venue is Middlesex County, where the cases are currently distributed among eight judges and involve plaintiffs from 13 states.
Although referred to as a class action, it is not a traditional one. Similar to the federal MDL, this would be a multicounty litigation, a coordinated mass tort structure that centralizes pretrial proceedings without consolidating the cases for trial. Each plaintiff retains an individual claim, but discovery, expert challenges, and motions are streamlined across the docket. The goal is efficiency, but the outcome often gives plaintiffs greater leverage, especially during early bellwether trials or global settlement discussions.
This approach is becoming increasingly common in mass torts. Law firms like Nguyen Injury Lawyer are increasingly choosing state courts to pursue complex drug injury claims, avoiding the procedural delays and evidentiary hurdles that have become prevalent in many federal MDLs. The current trajectory of the Ozempic MDL is one to avoid.
August 1, 2025 – MDL Case Count
As of today, the GLP-1 RA MDL 3072 has 2,190 pending cases. This litigation continues to experience a steady influx of new filings, underscoring the growing concerns about potential undisclosed risks associated with widely used diabetes and weight-loss medications such as Ozempic, Wegovy, and Mounjaro.
The majority of these claims involve gastroparesis lawsuits. Does this indicate renewed enthusiasm for the litigation? The honest answer is no. Nguyen Injury Lawyer is still accepting these cases, and there is cautious optimism regarding the MDL judge’s rulings on Daubert challenges. However, few experts are willing to confidently predict the outcome.
July 28, 2025 – New Study Links Ozempic to Retinal Vein Occlusion
A recent observational study from Sweden has revealed a potential link between semaglutide use and retinal vein occlusion (RVO). This serious eye condition can lead to sudden vision loss. The study, which analyzed insurance data from over 800,000 diabetic patients, found that users of GLP-1 receptor agonists like Ozempic had a 1.6 times higher risk of developing RVO compared to those on traditional diabetes therapies. While the authors advise further research, the findings add to the growing body of evidence suggesting that semaglutide may contribute to vascular eye damage. This emerging risk could further complicate Novo Nordisk’s defense in the ongoing wave of NAION lawsuits.
July 19, 2025 – Plaintiffs Seek Vision Track Within MDL
Plaintiffs’ leadership in the Ozempic MDL has filed a motion with Judge Pratter requesting the formal creation of a “Vision Injury Track” within MDL 3094. This proposed structure would group NAION and other ocular injury claims together to streamline discovery, expert development, and eventual bellwether selection. According to the motion, over 140 cases in the MDL now involve claims of partial or total blindness. Plaintiffs argue that the increasing number of vision-related injuries and their distinct factual and scientific issues warrant separate treatment from the gastroparesis claims. Defense counsel has not yet responded, but the motion indicates that NAION litigation is no longer a minor issue, and the Ozempic lawyers in the MDL do not want the New Jersey state court to take over this litigation.
July 15, 2025 – Texas Woman Sues Over Sudden Blindness After Ozempic Use
A new lawsuit filed in Travis County, Texas, alleges that a 52-year-old woman suffered sudden and irreversible blindness after using Ozempic for only six months. The complaint states that she developed NAION in one eye and lost 90 percent of her vision in a single day. Her attorneys argue that Novo Nordisk ignored warning signs in early clinical trials and failed to provide adequate warnings to physicians and patients. The lawsuit also cites recent studies suggesting that semaglutide may impair optic nerve blood flow.
This is one of several new cases in state courts outside the MDL, highlighting a broader trend: vision loss plaintiffs are increasingly willing to forego federal consolidation in favor of faster, more visible trials at the state level. According to Nguyen Injury Lawyer, this case is incredibly strong if these injuries can be linked to Ozempic.
June 24, 2025 – Beyond Just NAION: Ozempic and Wegovy Linked to Increased Risk of Vision Loss
A new study in JAMA Ophthalmology has added to the growing concerns about Ozempic and Wegovy, raising further issues regarding vision loss.
Researchers from the University of Toronto found that patients taking semaglutide, the active ingredient in both drugs, were twice as likely to develop neovascular age-related macular degeneration (nAMD). This disease gradually destroys central vision and often leads to permanent impairment.
The study examined nearly 140,000 patients with type 2 diabetes from 2020 to 2023. The risk was small in absolute terms, just over two in 1,000 for semaglutide users versus one in 1,000 for non-users. However, the increase was real and statistically significant. Researchers accounted for other known risk factors, including kidney function, smoking, and the use of insulin and metformin.
What is significant is not only the result but also the biological plausibility: GLP-1 drugs like Ozempic alter vascular and inflammatory pathways, mechanisms directly involved in macular degeneration. This should be important to doctors and patients alike.
Ozempic was not initially marketed as a weight loss miracle, but it became one. The public embraced it before scientific understanding caught up. Now that evidence is emerging, first regarding stomach paralysis and now vision problems, companies like Novo Nordisk will have to answer for both what they disclosed and what they failed to investigate.
June 21, 2025 – New NAION Lawsuit
In a new lawsuit filed on Thursday in New Jersey Superior Court, a man from Woodbridge, New Jersey, alleges that his use of the weight-loss drug Wegovy caused him to suffer non-arteritic anterior ischemic optic neuropathy, resulting in permanent vision loss.
According to the complaint, the plaintiff used Wegovy, a GLP-1 receptor agonist, and subsequently developed NAION.
The lawsuit claims that the drug’s manufacturers failed to adequately warn consumers and healthcare providers about the risk of NAION. The plaintiff alleges that the company knew or should have known of the potential for Wegovy to cause optic nerve damage, yet continued to market the drug without proper safety disclosures.
He is seeking compensatory and punitive damages for his injuries, ongoing medical treatment, and diminished quality of life.
June 17, 2025 – NAION Claims Are Heating Up
Twenty-one New Jersey plaintiffs who claim they suffered permanent vision loss after taking Ozempic or Wegovy are seeking to consolidate their lawsuits into a multicounty litigation against Novo Nordisk. They are asking New Jersey state courts to coordinate the increasing number of cases involving non-arteritic anterior ischemic optic neuropathy (NAION), a rare and irreversible eye condition. These plaintiffs argue that centralization would streamline discovery, reduce inconsistent rulings, and make the litigation more manageable as filings continue to increase, the same arguments that led to the gastroparesis MDL.
Notably, NAION claims are now attracting more attention from lawyers than the earlier wave of gastroparesis lawsuits. While stomach paralysis cases initiated the Ozempic litigation, the vision loss allegations are generating significant interest because the injuries are so severe.
Permanent blindness, especially when it develops suddenly and without prior warning, represents a particularly serious injury that is more likely to drive individual lawsuits, media coverage, and eventual jury trials. Nguyen Injury Lawyer is closely monitoring these developments.
As scientific studies continue to explore a possible causal link between GLP-1 receptor agonists and optic nerve damage, these cases will continue to gain prominence.
June 10, 2025 – NAION Warning
Momentum is growing behind calls for the FDA to take action regarding Ozempic’s potential vision risks. Several ophthalmologists and public health advocates are now urging the agency to require a black box warning on semaglutide drugs, including Ozempic, Wegovy, and Rybelsus, due to mounting evidence linking them to nonarteritic anterior ischemic optic neuropathy (NAION).
This follows recent reports in JAMA Ophthalmology and a Danish registry study suggesting a statistically significant association between semaglutide use and sudden vision loss events. Attorneys involved in the New Jersey multicounty litigation effort are amplifying the push for regulatory change, arguing that Novo Nordisk has long been aware of this potential risk but has failed to update its labeling accordingly.
A black box warning would represent a significant shift. It would not only alter physician prescribing practices but could also create new avenues of liability for failure to warn. For plaintiffs’ lawyers, it would be compelling evidence demonstrating that the dangers of NAION were both foreseeable and preventable. Nguyen Injury Lawyer believes this is a critical step.
Expect pressure to increase, especially as more independent case reports emerge and as media coverage highlights the life-altering nature of these injuries. This is no longer just a litigation story; it is rapidly becoming a public health issue. If you have experienced vision loss after taking Ozempic or Wegovy, contact Nguyen Injury Lawyer at (713) 747-7777 or visit https://www.nguyeninjurylawyer.com for a consultation.
June 2, 2025 – Early Defense Strategy Emerges in Vision Loss Cases
Novo Nordisk’s Defense Strategy: Shifting the Blame
Novo Nordisk is signaling its defense strategy in the NAION lawsuits: attributing the condition to pre-existing health issues. Recent filings suggest that diabetes, hypertension, and high cholesterol, common among Ozempic users, are known risk factors for optic nerve damage and vision loss. The company implies that any injuries suffered by plaintiffs may not be related to semaglutide exposure.
This tactic is common among pharmaceutical defense attorneys: portraying the condition as multifactorial to divert attention from the drug’s role. However, this approach carries risk when presented to a jury. Attorneys for the plaintiffs will argue that Novo Nordisk had a duty to warn, even if the drug only slightly increased the baseline risk. This is especially important since patients with diabetes are already susceptible to ocular damage and would exercise greater caution if fully informed.
This defense also disregards the growing scientific consensus that NAION events are occurring at a higher rate than expected in semaglutide patients. Some of the most severe injuries are appearing in individuals with no significant prior eye problems. If the litigation advances to expert testimony and case-specific discovery, juries may be unsympathetic to a company that dismisses catastrophic injuries as mere coincidence.
This is an early indication that the NAION litigation will not simply mirror the gastroparesis MDL but could become its own distinct battleground, with unique scientific questions, plaintiff demographics, and a higher potential for significant verdicts. If you or a loved one suffered vision loss after taking Ozempic, contact Nguyen Injury Lawyer at (713) 747-7777 or visit our website at https://www.nguyeninjurylawyer.com to discuss your legal options.
May 19, 2025 – Ozempic Vision Loss Lawsuits Filed Over NAION Side Effect
The Ozempic litigation is expanding, with multiple vision loss lawsuits filed against Novo Nordisk by patients who developed non-arteritic anterior ischemic optic neuropathy (NAION). This serious and potentially irreversible eye condition can lead to blindness after using Ozempic.
These lawsuits allege that Novo Nordisk failed to warn patients and doctors about the risk of NAION, despite evidence from clinical trials, post-marketing surveillance, and adverse event reports. The absence of any warning about vision loss or NAION on the current Ozempic label is particularly concerning, given the scientific literature and real-world reports suggesting a link between semaglutide (the active ingredient in Ozempic) and optic nerve damage.
These vision loss claims are expected to increase, with similar lawsuits involving Wegovy and Rybelsus, two other semaglutide drugs manufactured by Novo Nordisk, also in development. All three medications belong to the GLP-1 receptor agonist drug class and share similar pharmacological profiles. If you have experienced vision problems while taking any of these medications, contact Nguyen Injury Lawyer at (713) 747-7777 or visit our contact page at https://www.nguyeninjurylawyer.com/contact for a free consultation.
From a legal perspective, the argument is clear: patients were denied the opportunity to make an informed decision and would likely have declined Ozempic had they been properly warned. Plaintiffs’ lawyers are highlighting the company’s aggressive marketing tactics, including off-label promotion of Ozempic for weight loss, as further evidence that patient safety was sacrificed for profit.
For attorneys already handling Ozempic stomach paralysis or gallbladder injury claims, these vision loss lawsuits present a new and severe injury theory. NAION lawsuits may result in significantly higher settlements due to the life-altering nature of blindness and the complete lack of warnings.
April 22, 2025 – Oral Arguments Today
Novo Nordisk and Eli Lilly sought to dismiss the majority of claims in these lawsuits, arguing that many allegations were too vague to support legal action. Nguyen Injury Lawyer disagrees with this assessment, considering the depth and detail already provided in the master complaint.
These lawsuits involve specific gastrointestinal injuries and are not based on boilerplate allegations. Plaintiffs argue that the complaint specifically references recurring themes in the companies’ advertising strategies that overstated safety profiles and misled both patients and prescribers. This argument is difficult to refute, even for those who support these drugs.
Contrary to the defendants’ claim of a “kitchen sink” approach, the negligence claim deliberately encompasses a wide range of conduct to account for differing state laws applicable across individual cases. This strategy is a necessary feature of complex, nationwide litigation, not a flaw.
Furthermore, the assertion that the complaint lacks specific misrepresentations ignores the uniform and heavily branded manner in which these drugs were marketed to the public. Plaintiffs contend that these promotions, which saturated digital, print, and broadcast media, consistently omitted meaningful warnings—an omission that became especially problematic as internal safety signals and international regulatory developments emerged.
While it is difficult to predict the judge’s ruling, Nguyen Injury Lawyer believes the plaintiffs have a strong case. However, the outcome remains uncertain.
April 21, 2025 – New Study
A CDC-supported study published in the Annals of Internal Medicine found that semaglutide-related emergency room visits occurred an estimated 25,000 times between 2022 and 2023, with the majority of these visits occurring in 2023. Most of these visits involved semaglutide alone, almost always in injectable form, and were triggered by serious gastrointestinal issues or hypoglycemia. Many cases required hospitalization.
Defendants will likely downplay these findings by characterizing the overall rate of visits as “rare,” but this term does not accurately reflect the severity of the outcomes. Nearly 40 percent of hypoglycemia cases and 15 percent of gastrointestinal cases resulted in hospital stays. These are not minor side effects but serious medical events that require clear communication to patients and doctors. If you have experienced any of these side effects, contact Nguyen Injury Lawyer at (713) 747-7777 for a free consultation.
April 9, 2025 – The Battle Over Gastroparesis Without a Gastric Emptying Study
Eli Lilly and Novo Nordisk are attempting to undermine a significant portion of the plaintiffs’ case by seeking to block testimony from two key experts: Dr. Daniel Raines and Dr. Eliot Siegel. These experts have been instrumental in connecting the use of drugs like Ozempic and Mounjaro to gastroparesis, a condition that slows down digestion and causes severe symptoms such as nausea, vomiting, and stomach pain.
The defendants argue that unless a plaintiff has undergone a specific medical test—a gastric emptying study—to objectively confirm the diagnosis, the entire opinion should be dismissed. They essentially claim that symptoms alone are insufficient and that relying on clinical judgment or timing, such as the onset of symptoms during drug use and their cessation upon discontinuation, does not meet the legal standards for reliable scientific evidence. They are heavily relying on medical guidelines that recommend testing and portraying the experts’ methods as unscientific and unreliable for court purposes.
However, this is a strategic maneuver to disqualify potentially hundreds of claims from individuals who did not undergo formal testing, often because their doctors deemed it unnecessary once the symptoms subsided. If the court sides with the defense, a large number of plaintiffs could be excluded simply because they did not undergo a specific diagnostic process, even though their symptoms and timelines strongly suggest the drugs as the cause.
Excluding expert testimony would disregard standard medical practice. Doctors often rely on symptoms, clinical judgment, and patient response to medication cessation, particularly for drug-induced conditions that are temporary and resolve without invasive tests. Many plaintiffs did not undergo formal testing for various reasons, including symptom improvement after discontinuing GLP-1 drugs, leading their doctors to believe further workup was unnecessary.
Requiring objective testing in every case would unfairly penalize plaintiffs for following standard medical advice, effectively closing the courthouse doors to valid claims and setting an unrealistic and unfair legal standard that benefits drug companies at the expense of genuinely harmed patients. If you believe you have a claim, contact Nguyen Injury Lawyer at (713) 747-7777 to discuss your legal options.
March 17, 2025 – Eli Lilly Motion
Eli Lilly has filed a motion requesting the court to rule that a reliable diagnosis of gastroparesis must be based on contemporaneous objective testing.
The motion further seeks to exclude testimony from plaintiffs’ experts who argue that a gastroparesis diagnosis can be reliable without such testing. The company argues that objective testing is necessary to ensure medical reliability and prevent speculative diagnoses, which could undermine the scientific rigor of the case.
Nguyen Injury Lawyer believes that Eli Lilly’s motion is a clear attempt to impose an overly rigid standard for diagnosing gastroparesis, one that does not necessarily reflect real-world medicine or tort claims. While objective testing can be useful, doctors do not rely on it alone. Many diagnoses are based on a combination of symptoms, patient history, and clinical judgment, especially when tests are inconclusive or not always available. By attempting to exclude expert opinions that acknowledge these medical realities, Lilly seeks to alter how tort claims function.
This approach aligns with their broader effort to limit the number of claims against them. By reducing the number of diagnoses classified as valid, they aim to decrease the number of plaintiffs who can proceed with their cases. This motion is not about ensuring medical accuracy or justice but about creating legal barriers to weaken the plaintiffs’ ability to hold them accountable. Nguyen Injury Lawyer does not believe this motion will succeed.
February 26, 2025 – New NAION Study
A recent study published in JAMA Ophthalmology investigated the potential link between semaglutide and non-arteritic anterior ischemic optic neuropathy (NAION), a rare eye condition that can lead to sudden vision loss.
The research analyzed data from 37.1 million adults with type 2 diabetes, including over 810,000 new users of semaglutide. The findings indicated an increase in the relative incidence of NAION among semaglutide users compared to those not exposed to the drug, with an incidence rate of 14.5 cases per 100,000 person-years among semaglutide users.
While NAION may not occur frequently, Nguyen Injury Lawyer believes that patients should be warned about the risk of this serious eye problem so they can make informed decisions about whether to take the risk.
The authors of this study recommend that healthcare providers consider this increased risk when prescribing Ozempic, Rybelsus, and Wegovy and discuss it with patients as part of a comprehensive benefit-risk assessment. If you were not properly warned and suffered NAION, contact Nguyen Injury Lawyer at (713) 747-7777 to discuss your legal options.
January 28, 2025 – New Study, More Concern
A recent study published in JAMA Otolaryngology–Head & Neck Surgery has added another layer of concern to the growing Noro Nordisk Ozempic lawsuits and the broader litigation over GLP-1 receptor agonists. Nguyen Injury Lawyer believes there was already plenty of cause for concern.
The study analyzed data from over 350,000 adults with type 2 diabetes and found that patients initiating GLP-1RA therapy—including drugs like Ozempic and Mounjaro—had a significantly increased risk of being diagnosed with thyroid cancer within the first year of use compared to those prescribed other diabetes medications.
Like most single studies, this study does not definitively prove causation. The increased risk may be due to increased medical surveillance rather than the drug directly causing cancer. However, the findings raise further concerns about the potential risks of GLP-1 medications. Nguyen Injury Lawyer believes there is too much evidence suggesting potential harm associated with these drugs for these new “maybe” side effects to be ignored.
January 22, 2025 – New Study Throws More Cold Water on Ozempic
A new January 2025 study has raised additional concerns about Ozempic.
Ozempic’s Troubling Reality: A Closer Look at the Risks
Recent research has cast doubt on the widely touted benefits of Ozempic and similar GLP-1 receptor agonists (GLP-1RAs). While these drugs are often promoted as revolutionary treatments for diabetes and obesity, this new study highlights a concerning reality: Ozempic may not be as safe as it seems. The findings reveal a mix of health outcomes, including some benefits, but also significant risks that raise serious questions about the drug’s overall safety.
Although GLP-1RAs like Ozempic may lower the risk of dementia, heart disease, and certain infections, they are also linked to severe and potentially life-altering complications. The study identified increased risks of gastrointestinal disorders, kidney stones, arthritis, fainting, and drug-induced pancreatitis in patients using these medications. This adds to a growing body of evidence suggesting that Ozempic may not be as safe as advertised. Patients who relied on these medications to improve their health are now facing unexpected and painful consequences—consequences that drug manufacturers either ignored or failed to adequately warn about. This serves as another reminder that aggressive marketing, initial success, and positive media coverage do not always tell the whole story.
Does this mean Ozempic is a terrible drug that should be recalled? No. However, patients should be warned of the known risks. If you have questions, contact Nguyen Injury Lawyer at (713) 747-7777 for a free consultation. You can also visit our website at https://www.nguyeninjurylawyer.com or reach out through our contact page at https://www.nguyeninjurylawyer.com/contact.
Recent Developments in Ozempic Litigation
Stay informed about the latest updates in the Ozempic litigation:
December 20, 2024 – Saxenda Added to MDL
The Judicial Panel on Multidistrict Litigation has decided to expand the GLP-1 receptor agonist MDL to include claims involving Novo Nordisk’s Saxenda. However, the panel denied a request to include blood clot-related injuries, such as deep vein thrombosis and pulmonary embolism, citing concerns about increased complexity.
The MDL is primarily focused on gastrointestinal injuries like stomach paralysis and intestinal obstruction. Despite support from both plaintiffs and Novo Nordisk for including clotting-related claims, the JPML determined that these claims did not share enough commonalities with gastrointestinal injuries.
November 13, 2024 – New Lawsuit Filed
A new lawsuit has been filed in Philadelphia as part of the national MDL for glucagon-like peptide-1 receptor agonists (GLP-1 RAs). In this case, a Tennessee woman alleges that Novo Nordisk’s drugs, Ozempic and Wegovy, caused her to develop severe, chronic gastrointestinal injuries, including gastroparesis.
The plaintiff was prescribed Ozempic in 2022 to manage diabetes and weight. She soon began experiencing persistent vomiting, nausea, and extreme stomach discomfort. After ongoing symptoms, she underwent a gastric emptying study in early 2023, a diagnostic test widely regarded as the gold standard for diagnosing delayed gastric emptying or gastroparesis, which confirmed her condition. This objective test result is likely to be significant evidence in the litigation.
As with other similar lawsuits, her complaint alleges that Novo Nordisk failed to adequately warn users and healthcare providers of the drugs’ severe gastrointestinal risks, including gastroparesis, stomach paralysis, and intestinal blockages—risks the plaintiff argues the company either knew or should have known based on prior clinical studies and adverse event data. She also alleges that Novo Nordisk downplayed these risks in its marketing, portraying the drugs as safe, effective, and essential for weight management, while omitting critical information about the drugs’ serious side effects and the likelihood of weight regain if discontinued.
November 4, 2024 – The Growing Importance of Gastric Emptying Studies
The MDL judge has raised questions about whether plaintiffs can definitively prove that gastroparesis is caused by Ozempic, or even if an individual plaintiff can prove that they have gastroparesis. As a result, there is now increased emphasis on confirming a diagnosis of gastroparesis, amid concerns that a doctor’s diagnosis alone may not be sufficient.
This has led to a renewed focus on gastric emptying studies as a crucial element of proof in the GLP-1 agonist litigation. These studies, which measure the rate at which food leaves the stomach, are considered the most objective way to identify delayed gastric emptying, a primary symptom and clinical hallmark of gastroparesis.
As the litigation progresses, gastric emptying studies will likely be viewed as the key to substantiating claims that drugs like Ozempic can alter gastrointestinal motility. Presenting gastric emptying study results in court provides scientific support and helps distinguish true cases of gastroparesis from other digestive issues.
November 1, 2024 – Litigation Schedule
The established schedule for the litigation is as follows:
- July 2, 2025: Deadline for fact discovery
- July 16, 2025: Deadline for Plaintiffs to serve expert reports
- August 13, 2025: Deadline for Defendants to serve expert reports
- August 22, 2025: Deadline for Plaintiffs to serve rebuttal expert reports
- October 10, 2025: Deadline for all parties to complete expert depositions
- October 27, 2025: Deadline for submission of motions to exclude expert opinions under Rule 702 and initial briefs
- October 29, 2025: Deadline for submission of summary judgment motions and initial briefs
- December 3, 2025: Deadline for submission of briefs in opposition to Rule 702 motions
- December 16, 2025: Deadline for submission of briefs in opposition to summary judgment motions
- December 17, 2025: Deadline for submission of reply briefs in support of Rule 702 motions
- January 16, 2026: Deadline for submission of reply briefs in support of summary judgment motions
This timeline indicates a lengthy process. All of these steps are necessary to advance individual lawsuits and conduct further discovery on the defendants if we are successful. As a result, Ozempic lawyers are likely tightening their criteria, recognizing that this will be a long-term undertaking. If you are considering filing an Ozempic claim, be prepared for a potentially lengthy legal battle. Contact Nguyen Injury Lawyer at (713) 747-7777 for a free consultation. You can also visit our website at https://www.nguyeninjurylawyer.com or reach out through our contact page at https://www.nguyeninjurylawyer.com/contact.
October 29, 2024 – Quality Control Issues at Manufacturing Plant
The FDA recently cited Novo Nordisk’s main Ozempic and Wegovy production plant in Kalundborg, Denmark, for quality control issues. The issues involved a lack of proper information on the water used in production to ensure control over microorganisms. This facility, one of only two worldwide that manufactures semaglutide (the active ingredient in these drugs), is critical to Novo’s efforts to meet the growing demand for its popular obesity and diabetes medications. Previously, Novo’s North Carolina plant faced FDA citations for insufficient investigation into bacterial contamination.
These issues raise concerns that the company is repeating past mistakes by prioritizing maximum production and profit over safety, similar to what may have occurred when they initially rushed the product to market.
Understanding Ozempic
Ozempic (generically known as semaglutide) is a prescription medication used to manage type 2 diabetes. It belongs to a class of drugs called glucagon-like peptide-1 (GLP-1) receptor agonists. GLP-1 is a hormone that is released in response to food intake and helps regulate blood sugar levels.
There is also evidence that Ozempic can promote weight loss in people with obesity, even those without diabetes. While Ozempic is approved for managing type-2 diabetes, doctors have also prescribed it off-label for obesity and weight management.
Ozempic is manufactured by the Dutch pharmaceutical company Novo Nordisk, which specializes in the development and sale of diabetes drugs.
Novo Nordisk first developed Ozempic in 2012, and it was approved by the FDA and released on the U.S. market in December 2017. In 2021, a higher-dose version of Ozempic (sold under the brand name Wegovy) was also approved by the FDA.
Ozempic and other GLP-1 drugs work by stimulating insulin production after meals. GLP-1 is a naturally occurring peptide in the body that helps control blood sugar levels. GLP-1 agonists mimic the effects of this peptide, making them useful in treating type 2 diabetes.
This drug helps reduce blood sugar to normal levels. Ozempic also slows down the digestive process, which helps maintain normal glucose levels. It is administered as a once-weekly injection with a minimum dosage of 0.25 mg and a maximum dose of 1 mg.
In addition to its primary use for diabetes, the weight loss effects observed during clinical trials led to further exploration of the drug’s potential in this area. As a result, semaglutide has also been approved in higher doses under the name “Wegovy” for chronic weight management.
Ozempic is effective and has helped many patients. However, a crucial question remains: Did the drug maker adequately warn about all potential risks, ensuring that a minority of patients did not suffer unnecessarily?
Nguyen Injury Lawyer is focusing our efforts in 2026 on two claims: NAION and gastroparesis, with a particular focus on NAION cases (we are not taking many gastroparesis cases in 2026). If you have questions, contact Nguyen Injury Lawyer at (713) 747-7777 for a free consultation. You can also visit our website at https://www.nguyeninjurylawyer.com or reach out through our contact page at https://www.nguyeninjurylawyer.com/contact.
The Harsh Reality of Gastroparesis
Gastroparesis is a challenging condition characterized by malfunctioning stomach muscles. Normally, strong muscle movements help move food through the digestive system. However, in individuals with gastroparesis, these movements are either too slow or absent, making it difficult for the stomach to empty food properly.
This can disrupt digestion and lead to various problems, including nausea, vomiting (sometimes of undigested food), abdominal pain, bloating, severe dehydration, feeling full quickly when eating, undigested food remaining in the stomach, acid reflux, fluctuating blood sugar levels, loss of appetite, weight loss, malnutrition, and a diminished quality of life.
Unfortunately, there is currently no known cure for gastroparesis.
Imagine experiencing hunger pangs that prompt you to nourish your body, only to be met with pain, nausea, and vomiting every time you attempt to eat. If you are experiencing this, contact Nguyen Injury Lawyer at (713) 747-7777 for a free consultation. You can also visit our website at https://www.nguyeninjurylawyer.com or reach out through our contact page at https://www.nguyeninjurylawyer.com/contact.
This condition traps sufferers in a relentless cycle of discomfort. With a stomach that refuses to cooperate, the basic human need to eat becomes a battleground. Every meal is a calculation, a risk, and often a regret. The physical symptoms are just the beginning; the psychological toll is equally devastating. The constant worry about when the next flare-up will occur, the anxiety of eating in public, and the stress of managing a diet that is both safe and nourishing can be overwhelming. It is a miserable experience.
The pain and discomfort of gastroparesis are not fleeting. They linger and echo through every aspect of life, casting a shadow over daily activities and social interactions. The chronic nature of the condition means that relief is often temporary and incomplete, leaving sufferers to navigate a maze of treatments and dietary adjustments in search of some semblance of normalcy.
Gastroparesis is frequently misunderstood or overlooked, especially by those unfamiliar with its effects, which can make the experience even more isolating for sufferers. The symptoms of gastroparesis are non-specific and often resemble those of other conditions like functional dyspepsia, irritable bowel syndrome, or peptic ulcer disease. This can lead to frequent misdiagnosis or a failure to diagnose the condition at all.
Because it is an “invisible” illness, it is often disregarded by family and friends, making empathy hard to come by. As a result, many individuals with gastroparesis feel alone in their struggle, compounding their emotional and physical burden.
The misery of gastroparesis lies not only in its physical symptoms but also in the way it steals the simple pleasures of life, like enjoying a meal without fear or pain. It is a condition that demands constant vigilance and adaptation and tests the resilience of those it afflicts.
This Could Have Been Avoided
If you have questions, contact Nguyen Injury Lawyer at (713) 747-7777 for a free consultation. You can also visit our website at https://www.nguyeninjurylawyer.com or reach out through our contact page at https://www.nguyeninjurylawyer.com/contact.
The Basis for Ozempic Lawsuits
It’s understandably frustrating to discover that the medication prescribed to improve your health has instead introduced new risks, like cholecystitis or gastroparesis. The core question in Ozempic lawsuits is whether drug manufacturers adequately warned patients about these potential dangers, allowing them to make informed decisions about their healthcare.
Drug manufacturers have a fundamental responsibility to fully disclose the risks associated with their medications. Patients deserve the ability to weigh the benefits against the potential harms. This principle is at the heart of the Ozempic litigation.
NAION and Ozempic
In 2024, Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) emerged as a potential side effect of Ozempic. NAION occurs when blood flow to the optic nerve is blocked, potentially leading to sudden and irreversible vision loss.
While NAION is often associated with conditions like high blood pressure, diabetes, and high cholesterol, it can also occur unexpectedly due to the structure of the eye itself. This makes it a concerning and unpredictable risk.
The link between Ozempic and NAION is still under investigation. However, emerging research suggests that rapid fluctuations in blood glucose levels, which can occur with diabetes medications like Ozempic, may impair blood flow to the optic nerve, potentially triggering NAION in susceptible individuals.
Nguyen Injury Lawyer is actively investigating NAION cases related to Ozempic use. Given the severity of NAION and its potential connection to Ozempic, our attorneys believe that claims related to this condition could result in significant settlements reflecting the life-altering impact of sudden vision loss. We are dedicated to pursuing these claims and holding the responsible parties accountable. Contact Nguyen Injury Lawyer at (713) 747-7777 or through our website at https://www.nguyeninjurylawyer.com.
Why NAION Claims Stand Out
Unlike gastroparesis, NAION causes sudden and often permanent vision loss. This can make these claims easier to substantiate, as the injuries are severe, readily apparent, and less likely to be confused with pre-existing conditions. Such cases are more likely to result in higher settlement amounts.
Estimating Potential Ozempic Lawsuit Settlements
Predicting settlement values in new product liability cases is challenging, especially with the Ozempic gastroparesis lawsuits, which are relatively recent. The strength of the scientific evidence supporting these cases remains a key factor. However, victims understandably want to know the potential compensation they might receive.
Based on current information and with the assumption that causation can be established, Nguyen Injury Lawyer estimates that successful Ozempic lawsuits involving severe gastroparesis or death could potentially settle in the range of $400,000 to $700,000. However, less severe injury cases will likely result in lower payouts.
As we discussed in our April 5, 2024 update, the injuries involved in these lawsuits vary significantly. Cases involving temporary or quickly resolved issues will not command the same settlement value as those involving serious, permanent injuries. Contact Nguyen Injury Lawyer at (713) 747-7777 or through our website at https://www.nguyeninjurylawyer.com.
Financial Factors Influencing Ozempic Settlements
The substantial profits generated by Ozempic, Rybelsus, Wegovy, Trulicity, and Mounjaro could influence settlement dynamics in these cases. The manufacturers are financially capable of managing significant settlement costs.
Typically, drug companies prefer to prolong litigation. However, the manufacturers may be more inclined to settle Ozempic claims quickly to protect the drug’s reputation and continued sales. Adverse publicity from verdicts could lead to increased scrutiny and potentially impact their market position.
These companies might offer substantial settlements to resolve litigation swiftly, mitigating negative publicity and avoiding the exposure of further damaging evidence. This strategy can help maintain the brand’s market position and prevent the potential for higher compensation claims or punitive damages.
The hope is that the defendants will offer significant compensation to claimants sooner rather than later to circumvent the reputational damage and financial unpredictability associated with jury verdicts. Contact Nguyen Injury Lawyer at (713) 747-7777 or through our website at https://www.nguyeninjurylawyer.com.
New Ozempic Warning
On September 28, 2023, the FDA added a new warning to the Ozempic label regarding the potential risk of ileus, a blockage that prevents food or liquid from passing through the colon.
The warning states that ileus is a serious but rare side effect reported in patients taking Ozempic. Symptoms include abdominal pain, nausea, vomiting, and constipation, and patients experiencing these symptoms should contact their healthcare provider immediately.
The FDA also recommends that healthcare providers monitor patients on Ozempic for signs and symptoms of ileus and consider discontinuing the medication if ileus is suspected. This underscores the fact that the full range of risks associated with Ozempic is still being determined.
Key Allegation in Ozempic Lawsuits
Every Ozempic lawsuit centers on the allegation that Novo Nordisk failed to adequately warn patients and doctors about the serious risk of gastroparesis and vision loss, leaving them uninformed about dangers that could have influenced their decision to use the drug. Contact Nguyen Injury Lawyer at (713) 747-7777 or through our website at https://www.nguyeninjurylawyer.com.
The Central Issue: Failure to Warn
The primary claim in every Ozempic lawsuit is that Novo Nordisk failed to provide adequate warnings about the risk of developing gastroparesis as a side effect of the drug.
While the Ozempic label lists common adverse reactions like nausea, vomiting, diarrhea, abdominal pain, and constipation, it does not explicitly link these symptoms to gastroparesis or include them in the “Warnings and Precautions” section. Although the label mentions delayed gastric emptying in the context of drug interactions, it does not identify gastroparesis as a potential chronic condition resulting from Ozempic use.
Furthermore, Novo Nordisk’s promotional materials do not mention the risk of gastroparesis in the “Important Safety Information” section. Changes in labeling over time, such as removing specific guidance on side effects from the “Patient Counseling Information” section, may lead physicians to misinterpret symptoms like vomiting as minor or temporary.
Attorneys for Ozempic victims argue that Novo Nordisk was aware, or should have been aware, of the potential link between Ozempic and gastroparesis based on clinical studies, case reports, and medical literature. The core allegation is that the company failed to provide adequate warnings about this risk, which allegedly led to a lack of awareness in the medical community and affected prescribing decisions. Contact Nguyen Injury Lawyer at (713) 747-7777 or through our website at https://www.nguyeninjurylawyer.com.
It’s important to remember that the risk of gastroparesis is common across the GLP-1RA class of drugs, which includes medications like tirzepatide, exenatide, liraglutide, albiglutide, dulaglutide, and lixisenatide. Published literature on the association between gastroparesis and any GLP-1RA should have alerted manufacturers to the need for warnings about this risk to patients and prescribing physicians.
Ozempic lawsuits argue that adequate disclosure of the risks of gastroparesis would have influenced physicians’ decisions to prescribe Ozempic or to monitor for symptoms more closely. The failure to disclose this risk may be attributed to financial considerations, as more warnings could lead to fewer sales and reduced profits.
NAION Warning Case: A Stronger Argument
In June 2025, European regulators added non-arteritic anterior ischemic optic neuropathy (NAION) as a very rare side effect on the Ozempic label. NAION is a serious eye condition that can cause sudden, permanent vision loss due to disrupted blood flow to the optic nerve.
The updated warning advises patients to immediately stop taking Ozempic if they notice sudden changes in vision and to seek urgent medical care. Doctors in Europe are also being advised to discuss this risk with patients before prescribing semaglutide drugs such as Ozempic, Wegovy, or Rybelsus.
In the United States, the FDA has not yet added a specific NAION warning to the Ozempic label, although vision problems are mentioned more generally. This discrepancy highlights concerns about the full scope of risks associated with widely prescribed drugs like Ozempic. The recognition of NAION in Europe indicates that safety questions remain, and regulators are still working to define the true risks of this medication. Contact Nguyen Injury Lawyer at (713) 747-7777 or through our website at https://www.nguyeninjurylawyer.com.
Ozempic Class Action Lawsuit
In February 2024, the MDL panel certified an Ozempic class action lawsuit. A Multidistrict Litigation (MDL) class action can potentially expedite the settlement process in lawsuits like the Ozempic case through:
Streamlined Proceedings
MDLs consolidate similar cases to streamline the legal process, reducing duplicative discovery, avoiding conflicting rulings, and increasing efficiency. This consolidation can lead to quicker settlements by pressuring defendants to resolve many cases at once.
Higher Negotiation Leverage
The large number of consolidated cases in an MDL increases the plaintiffs’ leverage in settlement negotiations. This can encourage defendants like Novo Nordisk to settle to avoid the risk of facing a potentially large, cumulative judgment across many individual cases. Settlements in an MDL can offer compensation to claimants more quickly than individual lawsuits, which might take years to resolve.
Ozempic settlement amounts are unlikely to be uniform. If these claims are successful, payouts will vary depending on the severity of the side effects and the evidence supporting the plaintiffs’ claims. Contact Nguyen Injury Lawyer at (713) 747-7777 or through our website at https://www.nguyeninjurylawyer.com. You can also reach us through our contact page: https://www.nguyeninjurylawyer.com/contact.
Understanding MDLs vs. Class Action Lawsuits in Ozempic Litigation
Our attorneys often hear the Ozempic multidistrict litigation (MDL) mistakenly referred to as a class action lawsuit. While the terms are sometimes used interchangeably by the public, it’s important to understand the distinct legal mechanisms involved.
In a class action, a group of plaintiffs with similar injuries caused by the same defendant combine their cases into a single lawsuit. A designated class representative acts on behalf of the entire group, and any settlement or judgment applies to all class members. For a class action to proceed, the court must certify the class, confirming that the claims are sufficiently similar and that the representatives will adequately protect the class’s interests. In the Ozempic litigation, some class actions may address consumer claims for individuals who may not have suffered physical injuries.
An MDL, on the other hand, consolidates individual lawsuits with similar claims into a single court for pretrial proceedings, promoting efficiency and streamlining the process. Each plaintiff in an Ozempic MDL retains their individual lawsuit, which is transferred back to its original court for trial if a settlement isn’t reached during the MDL process. The primary purpose of an MDL is to manage complex cases involving numerous plaintiffs and shared factual issues more effectively.
In the Ozempic MDL, numerous individual cases related to the drug are consolidated for pretrial procedures. This allows for coordinated discovery and judicial efficiency while preserving the individuality of each plaintiff’s claim. Unlike a class action, the outcomes in an MDL can differ for each plaintiff based on the specific details of their case.
What Ozempic Patients Need to Know
If you experienced gastroparesis or vision loss after taking Ozempic, Wegovy, or another GLP-1 drug, you may be eligible for compensation. Lawsuits are currently consolidated in federal and state courts, and deadlines may apply. Contact Nguyen Injury Lawyer at (713) 747-7777 for a free consultation, or visit our contact page at https://www.nguyeninjurylawyer.com/contact.
Estimating Potential Settlement Amounts in Ozempic Lawsuits
Accurately estimating potential settlement values in new product liability cases like the Ozempic litigation is extremely challenging, especially given the novelty of the Ozempic gastroparesis lawsuits. The strength of the scientific evidence supporting these cases remains uncertain, which is a critical factor in any defective drug case.
However, our attorneys at Nguyen Injury Lawyer understand that victims want to know what to expect. While we cannot guarantee any specific outcome, we can offer an educated guess regarding potential settlement compensation ranges based on various assumptions about the causation evidence. Based on these assumptions, our attorneys believe that a successful Ozempic lawsuit involving severe gastroparesis or death could potentially yield a settlement value ranging from $200,000 to $500,000.
However, these represent the strongest cases. The average Ozempic gastroparesis lawsuit will likely result in a lower settlement. Many cases may involve temporary injuries, hospital stays, or less severe complications, potentially resulting in settlements ranging from $50,000 to $150,000, depending on the duration and impact of the condition. This assumes that the MDL judge allows the gastroparesis cases to proceed.
Some injuries caused by these drugs resolve relatively quickly, and those cases are unlikely to result in substantial payouts. However, cases involving severe and permanent injuries may have significant value.
NAION Settlements Could Be Substantial
The most serious potential cases involve NAION (non-arteritic anterior ischemic optic neuropathy), resulting in sudden and permanent vision loss. Blindness in one or both eyes significantly impacts all aspects of life and typically leads to higher settlement amounts when the defendant’s responsibility can be proven. Based on comparable drug injury cases, NAION-related Ozempic claims could reach $500,000 to $1 million or more, with bilateral blindness potentially exceeding those figures.
While no outcome is guaranteed, a tiered structure is evident. Less severe injuries will likely result in more modest payouts. Severe gastroparesis could potentially reach the mid-six figures. However, permanent vision loss from NAION represents a catastrophic injury that typically commands the largest settlements in this type of litigation.
Practical Factors Influencing Ozempic Settlements
The financial dynamics of the pharmaceutical market suggest the potential for significant payouts in the Ozempic litigation. The manufacturers are generating substantial profits from Ozempic, Rybelsus, Wegovy, Trulicity, and Mounjaro, placing them in a financial position to handle extensive settlement costs without jeopardizing their financial stability.
Drug companies often prefer to prolong litigation and may not be overly concerned about negative publicity from adverse verdicts. However, the potential impact on the drugs’ reputation and future sales may alter this calculus. Nguyen Injury Lawyer believes the substantial profits generated by these drugs may incentivize the companies to settle claims out of court more quickly to protect their profits and avoid the public relations fallout of adverse verdicts.
The expectation is that these defendants might offer substantial settlement payouts to resolve the litigation swiftly and mitigate any negative publicity that could arise during a trial. This strategy could help maintain the brand’s market position and potentially avoid the exposure of additional harmful evidence that could lead to even higher compensation claims or punitive damages.
Therefore, the hope is that defendants will offer significant compensation to claimants sooner rather than later to circumvent the reputational damage and financial unpredictability associated with jury verdicts.
Weight Loss Lawsuits May Have Higher Values Than Diabetes Cases
Nguyen Injury Lawyer anticipates that injury lawsuits for patients taking Ozempic and related drugs for diabetes will receive fair compensation if the claims are viable. However, settlement amounts for Ozempic in weight loss cases may be higher than those for diabetes claims due to several factors.
First, the use of Ozempic for weight loss may involve a different patient demographic, potentially including younger individuals who may experience longer-term or more severe impacts from side effects, thereby increasing the perceived damages. Younger patients generally receive higher settlement payouts than older patients in mass tort lawsuits.
Secondly, the expectations and marketing surrounding weight loss medications can create a higher perceived duty of care from pharmaceutical companies to disclose potential risks. If these risks are not adequately communicated, it could lead to greater liability and, consequently, higher settlements. Jurors may view the failure to warn of side effects in a medication used for lifestyle or cosmetic reasons as more egregious than one used for managing a chronic health condition like diabetes, potentially leading to a greater chance of winning a failure-to-warn claim and a larger punitive damages award.
Additionally, weight loss patients may not have the same underlying health issues as those with diabetes, making it easier to attribute certain side effects directly to the medication rather than pre-existing conditions. This clearer causation can strengthen claims and influence settlement outcomes.
When Will the Ozempic Lawsuit Be Settled?
The timeline for settling the Ozempic gastroparesis and NAION claims remains uncertain. The litigation is still in its early stages, and case-specific discovery has not yet begun. The Ozempic MDL is currently progressing through pretrial proceedings, focusing on establishing the general causation of the severe gastrointestinal risks associated with GLP-1 receptor agonists.
Nguyen Injury Lawyer does not anticipate any early Ozempic settlements or a large-scale resolution for several years. As the Ozempic litigation progresses, factors like bellwether trials—early test cases that gauge jury reactions—will shape potential settlement payouts. However, we are still years away from that point. Those affected should stay updated as more lawsuits against Ozempic continue to be filed and hope that our legal strategies continue to evolve so that we can hold manufacturers accountable.
Contact an Ozempic Attorney
If you have an Ozempic gastroparesis or NAION claim, contact Nguyen Injury Lawyer today at (713) 747-7777 or reach out to us online through our website at https://www.nguyeninjurylawyer.com for a free consultation.